Unknown

Dataset Information

0

Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.


ABSTRACT:

Background

MET dysregulation has been implicated in the development of primary and secondary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. However, the clinicopathological characteristics and outcomes of patients harboring EGFR-sensitive mutations and de novo MET amplifications still need to be explored.

Methods

A total of 54 patients from our hospital with non-small cell lung cancer harboring EGFR-sensitive mutations and/or de novo MET amplifications were included in this study. Survival rates were estimated by the Kaplan-Meier method with log-rank statistics. Lung cancer organoids (LCOs) were generated from patient-derived malignant pleural effusion to perform drug sensitivity assays.

Results

Fifty-four patients with the appropriate clinicopathological characteristics were enrolled. MET FISH was performed in 40 patients who were stratified accordingly into two groups: EGFR+/METamp- (n = 22) and EGFR+/METamp + (n = 18). Survival rates for EGFR+/METamp- and EGFR+/METamp + patients respectively, were as follows: the median progression-free survival (PFS) was 12.1 and 1.9 months (p<0.001); the median post-progression overall survival (pOS) was 25.6 and 11.6 months (p = 0.023); the median overall survival (OS) was 33.2 and 12.7 months (p = 0.013). Drug testing conducted in LCOs derived from malignant pleural effusion from EGFR+/METamp + patients showed that dual targeted therapy was more effective than TKI monotherapy.

Conclusion

EGFR+/METamp + patients treated with first-line TKI monotherapy had poor clinical outcomes. Dual targeted therapy showed potent anticancer activity in the LCO drug testing assay, suggesting that it is a promising first-line treatment for EGFR+/METamp + patients. Randomized controlled trials are needed to further validate these results.

SUBMITTER: Peng KC 

PROVIDER: S-EPMC9161327 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.

Peng Kai-Cheng KC   Su Jun-Wei JW   Xie Zhi Z   Wang Han-Min HM   Fang Mei-Mei MM   Li Wen-Feng WF   Chen Yu-Qing YQ   Guan Xu-Hui XH   Su Jian J   Yan Hong-Hong HH   Zhang Xu-Chao XC   Tu Hai-Yan HY   Zhou Qing Q   Chen Hua-Jun HJ   Wu Yi-Long YL   Yang Jin-Ji JJ  

Thoracic cancer 20220418 11


<h4>Background</h4>MET dysregulation has been implicated in the development of primary and secondary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. However, the clinicopathological characteristics and outcomes of patients harboring EGFR-sensitive mutations and de novo MET amplifications still need to be explored.<h4>Methods</h4>A total of 54 patients from our hospital with non-small cell lung cancer harboring EGFR-sensitive mutations and/or de novo MET amplifications were included i  ...[more]

Similar Datasets

| S-EPMC5323147 | biostudies-literature
| S-EPMC6473281 | biostudies-literature
| S-EPMC8717426 | biostudies-literature
| S-EPMC7979775 | biostudies-literature
| S-EPMC10485398 | biostudies-literature
| S-EPMC6000013 | biostudies-other
| S-EPMC9454126 | biostudies-literature
| S-EPMC8455549 | biostudies-literature
| S-EPMC3837609 | biostudies-literature
| S-EPMC8199488 | biostudies-literature